



(51) International Patent Classification:

C07D 403/12 (2006.01) A61K 31/505 (2006.01)
A61K 31/495 (2006.01)

(21) International Application Number:

PCT/GB2014/050655

(22) International Filing Date:

5 March 2014 (05.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2013/072250 6 March 2013 (06.03.2013) CN

(71) Applicant (for all designated States except MG): ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 2 Kingdom Street, London, Greater London W2 6BD (GB).

(72) Inventors: **LI, David, Yunzhi**; AstraZeneca R&D China, Innovation Center China, Zhangjiang Hi-Tech Park, Shanghai 201203 (CN). **WANG, Jiabing**; AstraZeneca R&D China, Innovation Center China, Zhangjiang Hi-Tech Park, Shanghai 201203 (CN). **YANG, Zhenfan**; AstraZeneca R&D China, Innovation Center China, Zhangjiang Hi-Tech Park, Shanghai 201203 (CN). **ZENG, Qingbei**; AstraZeneca R&D China, Innovation Center China, Zhangjiang Hi-Tech Park, Shanghai 201203 (CN). **ZHANG, Xiaolin**; AstraZeneca R&D China, Innovation

Center China, Zhangjiang Hi-Tech Park, Shanghai 201203 (CN).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR



(57) Abstract: The invention relates to compounds of formula(I), or a pharmaceutically acceptable salt thereof: Formula (I) which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.